EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Antiretroviral Use for HIV Prevention During Pregnancy: The Need to Strengthen Regulatory and Surveillance Systems in Africa

Robin Schaefer iD, L Donaldson, A Chigome, M Escudeiro Dos Santos, S Lamprianou, N Ndembi, J I Nwokike, P Nyambayo, V Palmi, F Renaud, M Gonzalez Tome, V Miller

Drug Safety · 2025-03 · 48 (3) · 209-216

DOI: 10.1007/s40264-024-01494-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, online erschienen am 26.01.2025. Verfasst von Robin Schaefer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Forum for Collaborative Research, University of California, Berkeley, Washington, DC, USA. rschaefer@forumresearch.org. Hauptthemen laut MEDLINE: Anti-HIV Agents, Anti-Retroviral Agents, HIV Infections, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: World Health Organization, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HIV-prevention efforts focusing on women of child-bearing potential are needed to end the HIV epidemic in the African region. The use of antiretroviral drugs as pre-exposure prophylaxis (PrEP) is a critical HIV prevention tool. However, safety data on new antiretrovirals during pregnancy are often limited because pregnant people are excluded from drug development studies. Calls from communities, healthcare professionals, and regulators to improve the information supporting decision-making around the use of medical products during pregnancy have been increasing. Post-marketing safety surveillance is an essential tool for detecting adverse outcomes and evaluating real-world, longer-term effects of drugs. Detecting and evaluating uncommon pregnancy outcomes requires large sample sizes, highlighting the benefits of and need for safety surveillance. Surveillance systems vary widely across Africa, and the need for enhanced surveillance of PrEP use during pregnancy highlights the limitations of current regulatory and surveillance systems. Challenges include weak regulation and insufficient resources. Pooling of resources and regulatory harmonization could address resource challenges. The African Medicines Agency, as a specialized agency of the African Union, has the potential to improve African medical product regulation, including post-marketing safety surveillance. This can strengthen regulation and ensure that market authorization holders meet their responsibility to invest in post-marketing surveillance systems, such as pregnancy registries. At the same time, independent post-marketing studies are needed to ensure generation of essential safety data. The Forum for Collaborative Research has initiated a project to facilitate interactions between regulators in Africa, the USA, and Europe, as well as other stakeholders, and to work toward consensus on safety data generation from PrEP during pregnancy before and after marketing authorization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsAnti-Retroviral AgentsHIV InfectionsPre-Exposure ProphylaxisPregnancy Complications, InfectiousProduct Surveillance, PostmarketingFemaleHumansPregnancyAfrica

Substanzen

Anti-HIV AgentsAnti-Retroviral Agents

Autor:innen und Institutionen

  • Forum for Collaborative Research, University of California, Berkeley, Washington, DC, USA. rschaefer@forumresearch.org.
  • Forum for Collaborative Research, University of California, Berkeley, Washington, DC, USA.
  • South African Health Products Regulatory Authority, Pretoria, South Africa.
  • Vaccines and Therapies for Infectious Diseases, Human Medicines Division, European Medicines Agency, Amsterdam, The Netherlands.
  • Pharmacovigilance team, Department of Regulation and Prequalification, World Health Organization, Geneva, Switzerland.
  • Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.

ORCID-Profile: Robin Schaefer

Förderung

  • World Health Organization
  • Bill and Melinda Gates Foundation

Zitieren

APA

Schaefer, R., Donaldson, L., Chigome, A., Escudeiro Dos Santos, M., Lamprianou, S., Ndembi, N., Nwokike, J. I., Nyambayo, P., Palmi, V., Renaud, F., Gonzalez Tome, M., & Miller, V. (2025). Antiretroviral Use for HIV Prevention During Pregnancy: The Need to Strengthen Regulatory and Surveillance Systems in Africa. Drug Safety, 48(3), 209-216. https://doi.org/10.1007/s40264-024-01494-6

Vancouver

Schaefer R, Donaldson L, Chigome A, Escudeiro Dos Santos M, Lamprianou S, Ndembi N, et al. Antiretroviral Use for HIV Prevention During Pregnancy: The Need to Strengthen Regulatory and Surveillance Systems in Africa. Drug Safety. 2025;48(3):209-216. doi:10.1007/s40264-024-01494-6

BibTeX
@article{Schaefer2025,
  author = {Schaefer, Robin and Donaldson, L and Chigome, A and Escudeiro Dos Santos, M and Lamprianou, S and Ndembi, N and Nwokike, J I and Nyambayo, P and Palmi, V and Renaud, F and Gonzalez Tome, M and Miller, V},
  title = {Antiretroviral Use for HIV Prevention During Pregnancy: The Need to Strengthen Regulatory and Surveillance Systems in Africa},
  journal = {Drug Safety},
  year = {2025},
  volume = {48},
  number = {3},
  pages = {209--216},
  doi = {10.1007/s40264-024-01494-6}
}
Kostenlos starten →